查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2020211

处方药市场规模、份额、成长率及全球产业分析：按类型、应用和地区划分，并预测至2026-2034年

Prescription Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 140 Pages | 商品交期: 请询问到货日

价格

处方药市场的成长要素

全球处方药市场预计在2025年达到13,244.4亿美元，2026年成长至1,4155.2亿美元，并在2034年达到2,4928.4亿美元。这意味着在预测期内，该市场将维持7.33%的强劲复合年增长率。北美将在2025年占据市场主导地位，市场份额高达49.66%，这主要得益于其高昂的医疗保健支出、先进的治疗方法以及专注于学名药和专科药物的大型製药企业的存在。光是美国处方药市场预计到2032年就将达到9.311亿美元，这主要得益于孤儿药核准的增加以及对专科药物需求的成长。

处方药包括疫苗、生物製药以及用于治疗癌症、心血管疾病、糖尿病和罕见疾病（孤儿病）等急性慢性疾病的治疗方法。近年来，市场发生了显着变化，包括学名药的涌入，这影响了整体市场渗透率和可及性。 2020年，新冠疫情导致市场暂时萎缩，原因是封锁措施、医院就诊限制和供应链中断，造成全球药品短缺和药品支出下降。根据美国卫生系统药剂师协会统计，2020年非联邦医院的处方药支出下降了4.6%。然而，常规医疗服务的重新开放、病患就诊量的增加以及研发投入的活性化，特别是针对新冠肺炎治疗的研发投入，都促进了市场的復苏。

市场趋势

拓展跨治疗领域的研发管线

製药公司加大研发投入是重要的市场趋势。 2021年，欧洲以研发为主导的製药公司在慢性病治疗药物的研发上投入了约436.842亿美元。各公司正日益关注孤儿药，并进行了大量临床试验。预计这将推动市场在预测期内成长。

学名药的普及

非专利处方药的上市是成长要素之一。 2019年10月，美国FDA核准了1,171种非专利处方药，促进了市场竞争，降低了药品价格。政府主导的倡议，例如印度的「奥沙迪计画」（Aushadi Scheme），使得非专利处方药的价格比原厂药低50%至90%，进一步促进了市场扩张。

罕见疾病孤儿药的研发

另一个重要因素是人们对孤儿药日益增长的关注。像BioMarin和Baudax Bio这样的公司正在研发罕见疾病疗法，孤儿药的核准加速了临床试验，最终使药物得以进入市场，并为此前服务不足的市场创造重磅药物的机会。

市场限制因素

儘管存在成长要素，但处方药的高成本限制了其市场渗透率。研发新药的成本可能高达26亿美元，而某些治疗方法，例如前列腺癌药物Abiraterone，每月费用可能高达1万美元，这使得药物的可及性难以负担，尤其是在发展中地区。

市场区隔

依产品类型

  • 其他处方药占据市场主导地位，预计到 2026 年将占全球整体的 71.71%。这主要是由于肿瘤药物、抗糖尿病药物和心血管药物的普及，而这些药物的学名药目前尚未广泛上市。
  • 孤儿药预计将以更高的复合年增长率成长，这得益于临床试验的增加和监管核准的扩大。
  • 学名药因其价格低廉且在新兴市场越来越受欢迎而受益。

按治疗领域

  • 肿瘤学领域处于主导，由于癌症的高发生率和标靶治疗的核准，预计到 2026 年，肿瘤学将占全球整体的 67.55%。
  • 其他细分市场包括中枢神经系统药物、疫苗和免疫抑制剂，所有这些市场预计都会因疾病盛行率上升和监管部门核准而成长。

透过分销管道

  • 由于重要药物通常需要专门的给药方式，因此医院药局是这些药物的主要来源。
  • 零售药局和网路药局都在发展，由于处方笺续药的便利性，预计网路药局的复合年增长率将最高。

区域趋势

  • 北美：受先进治疗方法和高额医疗保健支出的推动，预计2025年市场规模将达到6,576.8亿美元，2026年将达到7,030.4亿美元。其中，美国预计2026年市场规模将达6,076亿美元。
  • 欧洲：受学名药和孤儿药上市的推动，预计到 2025 年，该市场规模将达到 2,712.1 亿美元，到 2026 年将达到 2,887.7 亿美元。
  • 亚太地区：预计该地区到 2025 年将达到 3,005.7 亿美元的强劲规模，到 2026 年将达到 3,235 亿美元。日本、中国和印度是主要贡献者。
  • 预计到 2025 年，拉丁美洲和中东及非洲的经济成长将分别达到 616.4 亿美元和 333.3 亿美元，并有望持续成长至 2034 年。

主要企业及趋势

主要企业包括诺华、辉瑞、罗氏、赛诺菲、强生、默克、艾伯维、GlaxoSmithKline Plc和Astra Zeneca，以及专门生产学名药的公司，例如瑞迪博士实验室和鲁宾製药。近期发展如下：

  • 2023年10月：诺华公司剥离山德士，专注于创新药物。
  • 2023 年 1 月：安进公司在美国推出了其生物相似药「AMJEVITA」。
  • 2020-2022 年：鲁宾製药和瑞迪博士製药先后在美国推出了学名药和专科疗法。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第四章：主要考虑因素

  • 主要疾病流行情况－按主要国家划分，2026 年
  • 主要企业管道分析
  • 主要企业的关键产业趋势
  • 主要区域的监管状况
  • 新产品发布：按主要企业划分
  • 新冠疫情对市场的影响

第五章：2021-2034年全球处方药市场分析、洞察与预测

  • 市场分析、洞察与预测：按产品类型划分
    • 学名药
    • 孤儿药
    • 其他处方药
  • 市场分析、洞察与预测：按应用领域划分
    • 肿瘤学
    • 中枢神经系统
    • 疫苗
    • 免疫抑制剂
    • 其他的
  • 市场分析、洞察与预测：按分销管道划分
    • 医院药房
    • 零售药局和药房
    • 网路药房
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美处方药市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲处方药市场分析、洞察与预测（2021-2034年）

  • 国家
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 其他欧洲国家

第八章：亚太处方药市场分析、洞察与预测（2021-2034年）

  • 国家
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 东南亚
    • 其他亚太国家

第九章：拉丁美洲处方药市场分析、洞察与预测（2021-2034年）

  • 国家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲处方药市场分析、洞察与预测（2021-2034年）

  • 国家
    • GCC
    • 南非
    • 其他中东和非洲国家

第十一章 竞争分析

  • 全球市占率分析（2026 年）
  • 公司简介
    • Novartis AG
    • Pfizer, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Sanofi
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • AbbVie, Inc.
    • GlaxoSmithKline plc.
    • AstraZeneca
    • CELGENE CORPORATION（BRISTOL-MYERS SQUIBB COMPANY）
Product Code: FBI102709

Growth Factors of prescription drugs Market

The global prescription drugs market was valued at USD 1,324.44 billion in 2025 and is projected to grow to USD 1,415.52 billion in 2026, eventually reaching USD 2,492.84 billion by 2034, reflecting a robust CAGR of 7.33% during the forecast period. North America dominated the market in 2025 with a 49.66% share, primarily driven by high healthcare expenditure, advanced therapies, and the presence of major pharmaceutical companies focusing on generic and specialty medicines. The U.S. prescription drugs market alone is expected to reach USD 931.1 million by 2032, fueled by the increasing approval of orphan drugs and rising demand for specialty medications.

Prescription drugs encompass vaccines, biologics, and therapies used to manage both chronic and acute diseases such as cancer, cardiovascular disorders, diabetes, and rare (orphan) diseases. The market has witnessed significant changes in recent years, including an influx of generic equivalents, impacting overall adoption and accessibility. The COVID-19 pandemic caused a temporary decline in 2020 due to lockdowns, restricted hospital visits, and disruptions in supply chains, leading to shortages and reduced drug expenditures globally. According to the American Society of Health-System Pharmacists, prescription drug spending in nonfederal hospitals fell by 4.6% in 2020. However, the resurgence of routine healthcare services, increased patient visits, and rising R&D initiatives, particularly for COVID-19 treatments, contributed to renewed growth in the market.

Market Trends

Pipeline Expansion Across Therapy Areas

Increasing R&D investments by pharmaceutical companies are a critical trend in the market. In Europe, research-based pharmaceutical companies invested approximately USD 43,684.2 million in R&D in 2021 to develop drugs addressing chronic disorders. Companies are increasingly focusing on rare diseases (orphan drugs), with numerous clinical trials ongoing, which is expected to fuel market growth over the forecast period.

Generic Drug Adoption

The launch of generic equivalents is a key growth driver. In October 2019, the U.S. FDA approved 1,171 generic drugs, enhancing competition and making medications more affordable. Government initiatives, such as India's Aushadhi Scheme, offer generic drugs at 50-90% lower costs, further supporting market expansion.

Orphan Drugs Development

The increasing focus on orphan drugs is another major factor. Companies such as BioMarin and Baudax Bio are developing therapies for rare diseases, with orphan drug approvals enabling accelerated clinical trials and eventual market entry, creating opportunities for blockbuster drugs in previously underserved markets.

Market Restraints

Despite the growth drivers, high costs associated with prescription drugs limit market penetration. Developing a new drug can cost USD 2.6 billion, and certain therapies, such as Abiraterone for prostate cancer, may cost USD 10,000 per month, making affordability a challenge, particularly in developing regions.

Market Segmentation

By Product Type

  • Other Prescription Drugs dominate, accounting for 71.71% globally in 2026, driven by oncology, anti-diabetic, and cardiovascular medications without immediate generic equivalents.
  • Orphan drugs are expected to grow at a higher CAGR, supported by increasing clinical trials and regulatory approvals.
  • Generics benefit from affordability and increasing adoption in emerging markets.

By Therapy

  • Oncology leads, representing 67.55% globally in 2026, due to high cancer prevalence and targeted therapy approvals.
  • Other segments include central nervous system drugs, vaccines, immunosuppressants, and others, all showing growth driven by rising disease prevalence and regulatory approvals.

By Distribution Channel

  • Hospital pharmacies dominate, as critical medications often require professional administration.
  • Retail pharmacies and online pharmacies are growing, with online pharmacies expected to register the highest CAGR due to convenience in prescription refills.

Regional Insights

  • North America: Market size of USD 657.68 billion in 2025, projected to USD 703.04 billion in 2026, led by advanced therapies and high healthcare expenditure. The U.S. is expected to reach USD 607.6 billion in 2026.
  • Europe: Accounted for USD 271.21 billion in 2025, projected to USD 288.77 billion in 2026, driven by generic launches and orphan drugs.
  • Asia Pacific: Strong presence at USD 300.57 billion in 2025, projected to USD 323.5 billion in 2026, with Japan, China, and India being key contributors.
  • Latin America & Middle East & Africa: Represent USD 61.64 billion and USD 33.33 billion respectively in 2025, with steady growth expected through 2034.

Key Companies & Developments

Major players include Novartis AG, Pfizer, Roche, Sanofi, Johnson & Johnson, Merck, AbbVie, GlaxoSmithKline, and AstraZeneca, alongside generic-focused companies like Dr Reddy's Laboratories and Lupin Pharmaceuticals. Recent developments include:

  • October 2023: Novartis spun off Sandoz to focus on innovative medicines.
  • January 2023: Amgen launched biosimilar AMJEVITA in the U.S.
  • 2020-2022: Multiple launches of generic and specialty drugs by Lupin and Dr. Reddy's in the U.S.

Conclusion

The global prescription drugs market is on a sustained growth trajectory from USD 1,324.44 billion in 2025 to USD 2,492.84 billion in 2034, driven by chronic and rare disease prevalence, increased R&D, generic drug adoption, and rising specialty medication approvals. While high costs may restrain some adoption, regional government initiatives, pipeline expansion, and innovations in hospital and homecare therapies ensure robust market expansion. North America remains the dominant market, with Asia Pacific emerging as a high-growth region due to expanding healthcare infrastructure and rising awareness of chronic diseases.

Segmentation By Product Type

  • Generics
  • Orphan
  • Other Prescription Drugs

By Application

  • Oncology
  • Central Nervous System
  • Vaccines
  • Immunosuppressants
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Others

By Geography

  • North America (By Product Type, By Application, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Product Type, By Diabetes Type, By Distribution Channel, and By Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases - By Key Countries/ Region, 2026
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Key Industry Developments, By Key Players
  • 4.4. Regulatory Scenario, By Key Regions
  • 4.5. New Product Launches, By Key Players
  • 4.6. Impact of COVID-19 on the Market

5. Global Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Generics
    • 5.1.2. Orphan
    • 5.1.3. Other Prescription Drugs
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Oncology
    • 5.2.2. Central Nervous System
    • 5.2.3. Vaccines
    • 5.2.4. Immunosuppressants
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies & Drug Stores
    • 5.3.3. Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Generics
    • 6.1.2. Orphan
    • 6.1.3. Other Prescription Drugs
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Oncology
    • 6.2.2. Central Nervous System
    • 6.2.3. Vaccines
    • 6.2.4. Immunosuppressants
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies & Drug Stores
    • 6.3.3. Online Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Generics
    • 7.1.2. Orphan
    • 7.1.3. Other Prescription Drugs
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Oncology
    • 7.2.2. Central Nervous System
    • 7.2.3. Vaccines
    • 7.2.4. Immunosuppressants
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies & Drug Stores
    • 7.3.3. Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Rest of Europe

8. Asia Pacific Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Generics
    • 8.1.2. Orphan
    • 8.1.3. Other Prescription Drugs
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Oncology
    • 8.2.2. Central Nervous System
    • 8.2.3. Vaccines
    • 8.2.4. Immunosuppressants
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies & Drug Stores
    • 8.3.3. Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Generics
    • 9.1.2. Orphan
    • 9.1.3. Other Prescription Drugs
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Oncology
    • 9.2.2. Central Nervous System
    • 9.2.3. Vaccines
    • 9.2.4. Immunosuppressants
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies & Drug Stores
    • 9.3.3. Online Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. Generics
    • 10.1.2. Orphan
    • 10.1.3. Other Prescription Drugs
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Oncology
    • 10.2.2. Central Nervous System
    • 10.2.3. Vaccines
    • 10.2.4. Immunosuppressants
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies & Drug Stores
    • 10.3.3. Online Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2026)
  • 11.2. Company Profiles
    • 11.2.1. Novartis AG
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer, Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. F. Hoffmann-La Roche Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Johnson & Johnson Services, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Merck & Co., Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. AbbVie, Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. GlaxoSmithKline plc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. AstraZeneca
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. CELGENE CORPORATION (BRISTOL-MYERS SQUIBB COMPANY)
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Prescription Drugs Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 2: Global Prescription Drugs Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 3: Global Prescription Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Prescription Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Prescription Drugs Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 6: North America Prescription Drugs Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 7: North America Prescription Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Prescription Drugs Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Prescription Drugs Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 10: Europe Prescription Drugs Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 11: Europe Prescription Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Prescription Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Prescription Drugs Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 14: Asia Pacific Prescription Drugs Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 15: Asia Pacific Prescription Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Prescription Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Prescription Drugs Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 18: Latin America Prescription Drugs Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 19: Latin America Prescription Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Prescription Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Prescription Drugs Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 22: Middle East & Africa Prescription Drugs Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 23: Middle East & Africa Prescription Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Prescription Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Prescription Drugs Market Revenue Breakdown (USD billion, %) by Region, 2026 & 2034
  • Figure 2: Global Prescription Drugs Market Value Share (%), by Product Type, 2026 & 2034
  • Figure 3: Global Prescription Drugs Market Value Share (%), By Application, 2026 & 2034
  • Figure 4: Global Prescription Drugs Market Value Share (%), by Distribution Channel, 2026 & 2034
  • Figure 5: Global Prescription Drugs Market Value (USD billion), by Region, 2026 & 2034
  • Figure 6: North America Prescription Drugs Market Value (USD billion), by Product Type, 2026 & 2034
  • Figure 7: North America Prescription Drugs Market Value Share (%), by Product Type, 2026
  • Figure 8: North America Prescription Drugs Market Value (USD billion), By Application, 2026 & 2034
  • Figure 9: North America Prescription Drugs Market Value Share (%), By Application, 2026
  • Figure 10: North America Prescription Drugs Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 11: North America Prescription Drugs Market Value Share (%), by Distribution Channel, 2026
  • Figure 12: North America Prescription Drugs Market Value (USD billion), By Country, 2026 & 2034
  • Figure 13: North America Prescription Drugs Market Value Share (%), By Country, 2026
  • Figure 14: Europe Prescription Drugs Market Value (USD billion), by Product Type, 2026 & 2034
  • Figure 15: Europe Prescription Drugs Market Value Share (%), by Product Type, 2026
  • Figure 16: Europe Prescription Drugs Market Value (USD billion), By Application, 2026 & 2034
  • Figure 17: Europe Prescription Drugs Market Value Share (%), By Application, 2026
  • Figure 18: Europe Prescription Drugs Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 19: Europe Prescription Drugs Market Value Share (%), by Distribution Channel, 2026
  • Figure 20: Europe Prescription Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 21: Europe Prescription Drugs Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 22: Asia Pacific Prescription Drugs Market Value (USD billion), by Product Type, 2026 & 2034
  • Figure 23: Asia Pacific Prescription Drugs Market Value Share (%), by Product Type, 2026
  • Figure 24: Asia Pacific Prescription Drugs Market Value (USD billion), By Application, 2026 & 2034
  • Figure 25: Asia Pacific Prescription Drugs Market Value Share (%), By Application, 2026
  • Figure 26: Asia Pacific Prescription Drugs Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 27: Asia Pacific Prescription Drugs Market Value Share (%), by Distribution Channel, 2026
  • Figure 28: Asia Pacific Prescription Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 29: Asia Pacific Prescription Drugs Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 30: Latin America Prescription Drugs Market Value (USD billion), by Product Type, 2026 & 2034
  • Figure 31: Latin America Prescription Drugs Market Value Share (%), by Product Type, 2026
  • Figure 32: Latin America Prescription Drugs Market Value (USD billion), By Application, 2026 & 2034
  • Figure 33: Latin America Prescription Drugs Market Value Share (%), By Application, 2026
  • Figure 34: Latin America Prescription Drugs Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 35: Latin America Prescription Drugs Market Value Share (%), by Distribution Channel, 2026
  • Figure 36: Latin America Prescription Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 37: Latin America Prescription Drugs Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 38: Middle East & Africa Prescription Drugs Market Value (USD billion), by Product Type, 2026 & 2034
  • Figure 39: Middle East & Africa Prescription Drugs Market Value Share (%), by Product Type, 2026
  • Figure 40: Middle East & Africa Prescription Drugs Market Value (USD billion), By Application, 2026 & 2034
  • Figure 41: Middle East & Africa Prescription Drugs Market Value Share (%), By Application, 2026
  • Figure 42: Middle East & Africa Prescription Drugs Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 43: Middle East & Africa Prescription Drugs Market Value Share (%), by Distribution Channel, 2026
  • Figure 44: Middle East & Africa Prescription Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 45: Middle East & Africa Prescription Drugs Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 46: Global Prescription Drugs Market Share (%), By Company, 2026